← Leaderboards
Michael Schotsaert
Icahn School Of Medicine At Mount Sinai
$3,271,645
Attributed
$7,484,140
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,484,140 · 6
By mechanism
R01$4,207,189 · 2
R44$1,881,701 · 1
R21$1,395,250 · 3
Top collaborators
- Pamela Tinmoi Wong8 shared
- Dirk Homann3 shared
- Siddhartha De2 shared
- Upendra Marathi2 shared
- Juergen A Richt2 shared
- William Schary2 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Florian Krammer$130,401,178
- Viviana A Simon$21,556,427
- Benjamin Goldman-Israelow$1,110,912
- Allen Zheng$179,804
- Ernesto Guccione$11,143,318
Others in their field
Other Emerging Leaders on “Infection”
- Chanza Baytop · Westat, Inc.$271,217,917
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$207,651,224
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
Research focus
InfectionImmuneResponseVirusImmune ResponseVaccinationVaccinesInfluenzaInfluenzavirusImmunityVirus DiseasesViralMouse Model2019-NcovMorbidity - Disease RateDoseAdjuvantMucous MembranePathway InteractionsReceptorFutureAgonistInfluenza VaccinationInfluenza Virus Vaccine
Grant awards (15)
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$721,321
R01 · FY2025 · AI
Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection$208,000
R21 · FY2025 · AI · contact PI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953,477
R44 · FY2024 · AI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$725,845
R01 · FY2024 · AI
Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection$264,250
R21 · FY2024 · AI · contact PI
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity$204,750
R21 · FY2024 · AI · contact PI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928,224
R44 · FY2023 · AI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$725,288
R01 · FY2023 · AI
Experimental and natural SARS-CoV-2 infection of the human pancreas$418,396
R01 · FY2023 · DK
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity$261,000
R21 · FY2023 · AI · contact PI
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$744,600
R01 · FY2022 · AI
Experimental and natural SARS-CoV-2 infection of the human pancreas$418,419
R01 · FY2022 · DK
Experimental and natural SARS-CoV-2 infection of the human pancreas$453,320
R01 · FY2021 · DK
A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A Virus$198,829
R21 · FY2021 · AI · contact PI
A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A Virus$258,421
R21 · FY2020 · AI · contact PI